Terms ending in 2027
Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,790,726 | Monocyclic and Bicyclic Compounds and Methods of Use In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 7,524,845 | Azaindazole Compounds and Methods of Use In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 8,637,043 | Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 7,807,704 | Bicyclic, Nitrogen-Containing Compounds Modulating CXCR4 And/Or CCXCKR2 In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 7,649,011 | Inhibitors of Human Tumor-Expressed CCXCKR2 In force · High confidence | Chemocentryx | In force | High confidence | |
| US 7,777,035 | Azaindazole Compounds and Methods of Use In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 7,572,600 | Enzymatic Activities in Chemokine-Mediated Inflammation In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 7,671,069 | Tricyclic, Heteroaromatic Compounds Modulating CXCR4 And/ or CXCR7 In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 7,683,176 | Triazolyl Pyridyl Benzenesulfonamides In force · High confidence | Chemocentryx, Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.